


Washington State Life Science Investment Report February 2023

A monthly report summarizing life science transactions in Washington State.


BY THE NUMBERS: **5** TRANSACTIONS TOTALING OVER **\$78.4M** (YTD)

- Biotech/Pharma
- Medtech
- Digital Health
- Other

Deals Per Sector



Disclosed Funding By Sector



FEBRUARY TOP TRANSACTIONS

Cadence Neuroscience develops technology that detects specific signals from the brain and delivers electrical stimulation to modify the activity of neural circuits. The company's technology provides a personalized approach with unprecedented potential to treat many neurological diseases that cannot be adequately addressed with available treatment options (S&P Global Market Intelligence).

Abacus Bioscience, a biotech startup spun out of the University of Washington and led by veterans of Seattle-area biotech giant Seagen, has raised \$4.4M, part of an ongoing seed round ([GeekWire](#)).

**Pending transactions noted here are included in financial data only upon closing.*

OTHER TRENDS & HIGHLIGHTS

Life Science Real Estate Normalizes in Q4. Metrics gauging the life sciences sector varied to end 2022 as the industry normalized in the fourth quarter after robust growth in 2021 and much of 2022, according to a new report from CBRE ([425 Business](#)).

Tasso's TassoOne Plus blood collection device successfully met the requirements of the EU's new and somewhat cumbersome Medical Device Regulation, allowing it to be used by healthcare providers and academic and pharmaceutical researchers across the continent ([FierceBiotech](#)).

Anavasi Diagnostics receives FDA emergency use authorization for the AcencioDx COVID-19 test and the AscencioDx molecular detector. The AscencioDx[®] COVID-19 Test provides results for the detection of SARS-CoV-2 RNA in as little as 20 minutes ([BioSpace](#)).

TRANSACTIONS

Date	Company	Sector	Type	Amount	Location
03-Feb-2023	Abacus Bioscience	Biotech	Seed	\$4,410,000	Sammamish
28-Feb-2023	Cadence Neuroscience	Digital Health	Later Stage VC	\$26,030,000	Redmond
Disclosed transactions monthly totals:					
				February Total:	\$30,440,000
				January Total:	<u>\$48,000,000</u>